Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

A study in pigs has shown that the active ingredient in Ozempic and Wegovy directly boosts heart health, in addition to the ...

The medications are so common now, two-thirds of the clinic’s calls for insurance pre-authorizations are for the big three: ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...

(AP Photo/Manuel Balce Ceneta) WASHINGTON — Millions of Americans with obesity would be eligible to have popular weight-loss ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

This comes after both Maccabi and Meuhedet Health Services announced the same subsidy for the Mounjaro weight loss shot.

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?